Updated data from the APT trial shows that after 10 years of follow-up, adjuvant paclitaxel and trastuzumab confirm excellent long-term outcomes for small, node-negative HER2-positive breast cancer.
View Full Profile
So my name is Sarah titanium, a breast medical oncologist at Dana Farber Cancer Institute. And at san Antonio breast cancer conference. Today I'm presenting an analysis that looked at genomic predictors of benefit and resistance to checkpoint inhibition in metastatic triple negative breast cancer. We have data to suggest that adding checkpoint inhibitors to chemotherapy in patients with PD L one positive metastatic triple negative breast cancer improves outcomes. But we know however, that not all patients with PD L. One positive disease benefit and many developed resistance. So we looked at 31 patients at Dana Farber who had received checkpoint inhibition and looked at immune profiling as well as genomic analyses with whole XOM and RNA sequencing on tumors at baseline on study and at time of progression to better understand predictors of benefit and resistance. We found that PD L. One positivity by multiplex immuno fluorescence was associated with benefit to immunotherapy. However, CD four CD eight and P. D. One status was not. We also looked at genomic predictors and found that tumor mutation burden was associated with better progression free and overall survival to checkpoint inhibition. We also saw that patient to a durable benefit to immunotherapy had enrichment of follicular helper T cells as well as C. D. Four memory cells. Further work is ongoing. Looking at other predictors of benefit and resistance
